Concurrently, type 2 immunity (IL10 and IL4) has been linked to progression to NASH, and the elevation of plasma IL4, IL5, and IL13 is reported in patients with NASH (55). This evidence concerns the gene IL10 and metabolic dysfunction-associated steatohepatitis.